Capacity Building
WANETAM 3
at a glance
TARGET
Tuberculosis, HIV/AIDS and Malaria
TIMELINE
08 January 2021 to 31 December 2023
COORDINATOR
Reseau Africain de Recherche sur le SIDA
FUNDER
EDCTP
FUNDING
4.5 Mio Euro
SUMMARY
West African Network for TB, AIDS and Malaria
West African Network of Excellence for tuberculosis (TB), AIDS, and Malaria (WANETAM), comprises 19 institutions in 10 countries.
WANETAM3 will build on the activities of disease-defined work packages (WPs)on TB, Malaria, HIV/AIDS, Neglected Tropical Diseases, Emerging Infections response and preparedness, and the inclusion of the Cross-Cutting Training that strengthens capacity of individuals in specialised skills needed in clinical research and the capacity of supporting infrastructure.
The WPs will consolidate the project’s mission to achieve sustainable capacity and multi-institutional collaboration in clinical research through activities that premise on:
1. Strategic Project-based training to build Research leadership
2. Hands-on operational and clinical studies that inform clinical trial plans and prevention
3. Resource & Platform Infrastructure development
4. Surveillance to build evidence-base for clinical trial
5. Diagnosis to support intervention, and
6. Building on quality assurance and expanding laboratory accreditation.
PARTNERS
Centre Intégré de Recherche Bioclinique d’Abidjan (CIRBA), Côte d'Ivoire; Centre MURAZ (CM), Burkina Faso; Centre National de Recherche et de Formation sur le Paludisme (CNRFP), Burkina Faso; Clinical Research Unit of Nanoro, Burkina Faso; College of Medicine - University of Ibadan, Nigeria; College of Medicine and Allied Health Sciences (COMAHS), Sierra Leone; European Vaccine Initiative (EVI), Germany; Fondation pour la Recherche Scientific (FORS), Benin; Forschungszentrum Borstel Leibniz-Zentrum fur Medizin und Biowissenschaften (FZB), Germany; Groupe de Recherche Action en Santé (GRAS), Burkina Faso; Hôpital National Donka, CHU Conakry, Guinea; Institut de Recherche pour le Développement (IRD), France; Institut Pasteur de Dakar, Senegal; Institute of Human Virology Nigeria LTDGTE (IHVN), Nigeria; Instituto Nacional de Saúde Pública, Guine Bissau (INASA), Guinea-Bissau; Jos University Teaching Hospital, Nigeria; Korle-Bu Teaching Hospital, Ghana; London School of Hygiene and Tropical Medicine (LSHTM), United Kingdom; National Public Health Laboratory (NPHL), Gambia; Nigerian Institute of Medical Research (NIMR), Nigeria; Noguchi Memorial Institute for Medical Research (NMIMR), Ghana; Medical Research Council at London School of Hygiene and Tropical Medicine The Gambia (MRCG at LSHTM), The Gambia; Programme National de Lutte contre la Tuberculose – Benin, Benin; Programme National de Lutte contre la Tuberculose (PNLT - Togo), Togo; Programme National de Lutte contre le Sida Benin (PNS Benin),Benin; Réseau Africain de Recherche sur le SIDA/ Institut de Recherche en Santé, de Surveillance Epidémiologique et de Formations (RARS/IRESSEF), Senegal; Universidade Nova de Lisboa (NOVA), Portugal; Université Cheikh Anta Diop, Senegal; Université de Lomé, Togo; University of Sciences and Technology (USTTB), Mali.
This project is part of the EDCTP2 Programme supported by the European Union (CSA2020NoE-3103). The views and opinions of authors expressed herein do not necessarily state or reflect those of EDCTP.